Yang Zheng1,2, Zhao Wang1,3, Xu Ding1,2, Yibo Dong1,2, Wei Zhang1,4, Wei Zhang1,4, Yi Zhong1,4, Wenyi Gu3, Yunong Wu1,2, Xiaomeng Song1,2. 1. Key Laboratory of Oral Diseases of Jiangsu Province, Stomatological Institute of Nanjing Medical University, Nanjing, China. 2. Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, China. 3. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Qld., Australia. 4. Department of Oral Pathology, Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, China.
Abstract
OBJECTIVES: Head and neck squamous cell carcinoma (HNSCC) is characterized by high mortality and low survival rates. As an epidermal growth factor receptor (EGFR) inhibitor, Erlotinib has been approved for treatment of various tumours. PF-03084014 is a selective inhibitor of Notch1 signalling. This study aimed to explore new approaches for simultaneously targeting EGFR and Notch1 signalling to attenuate tumour growth and improve survival. MATERIALS AND METHODS: Cell proliferation was determined by CCK-8 assay and Flow cytometry. Cell invasive ability was determined by Transwell assay. Western blot was used to test the expression of Notch1 and EGFR pathway. Cleaved Caspase-3 staining and TUNEL assay were used to verify the apoptosis through combined treatment. RESULTS: We first confirmed proliferative inhibition and cell death in HNSCC with combined Erlotinib and PF-03084014 treatment. Moreover, we found PF-03084014 reversed the increased invasion induced by Erlotinib. In a preclinical therapeutic drug trial in vivo, combined treatment effectively abrogated tumour growth. Most importantly, one mechanism was found that PF-03084014 alone could activate the PI3K/AKT signalling, the downstream of EGFR signalling, and Erlotinib alone could activate the intracellular domain of Notch1 (NICD), while combined treatment of PF-03084014 and Erlotinib suppressed the HNSCC growth. CONCLUSIONS: These results suggested that concomitant inhibition of the Notch1 and EGFR pathways represented a rational strategy for promoting apoptosis in HNSCC and overcoming treatment resistance.
OBJECTIVES: Head and neck squamous cell carcinoma (HNSCC) is characterized by high mortality and low survival rates. As an epidermal growth factor receptor (EGFR) inhibitor, Erlotinib has been approved for treatment of various tumours. PF-03084014 is a selective inhibitor of Notch1 signalling. This study aimed to explore new approaches for simultaneously targeting EGFR and Notch1 signalling to attenuate tumour growth and improve survival. MATERIALS AND METHODS: Cell proliferation was determined by CCK-8 assay and Flow cytometry. Cell invasive ability was determined by Transwell assay. Western blot was used to test the expression of Notch1 and EGFR pathway. Cleaved Caspase-3 staining and TUNEL assay were used to verify the apoptosis through combined treatment. RESULTS: We first confirmed proliferative inhibition and cell death in HNSCC with combined Erlotinib and PF-03084014 treatment. Moreover, we found PF-03084014 reversed the increased invasion induced by Erlotinib. In a preclinical therapeutic drug trial in vivo, combined treatment effectively abrogated tumour growth. Most importantly, one mechanism was found that PF-03084014 alone could activate the PI3K/AKT signalling, the downstream of EGFR signalling, and Erlotinib alone could activate the intracellular domain of Notch1 (NICD), while combined treatment of PF-03084014 and Erlotinib suppressed the HNSCC growth. CONCLUSIONS: These results suggested that concomitant inhibition of the Notch1 and EGFR pathways represented a rational strategy for promoting apoptosis in HNSCC and overcoming treatment resistance.
Authors: Mark Agulnik; Gilda da Cunha Santos; David Hedley; Trudey Nicklee; Patricia Pintor Dos Reis; James Ho; Gregory R Pond; Heidi Chen; Shuo Chen; Yu Shyr; Eric Winquist; Denis Soulieres; Eric X Chen; Jeremy A Squire; Paula Marrano; Suzanne Kamel-Reid; Janet Dancey; Lillian L Siu; Ming S Tsao Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Myung-Ju Ahn; Byeong-Bae Park; Jin Seok Ahn; Sang We Kim; Heung-Tae Kim; Jong Seog Lee; Jin Hyung Kang; Jae Yong Cho; Hong Suk Song; Se Hoon Park; Chang Hak Sohn; Sang Won Shin; Jin Hyuck Choi; Chang-Seok Ki; Chan Keum Park; Alison J Holmes; Pasi A Jänne; Keunchil Park Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: J G Aerts; H Codrington; N A G Lankheet; S Burgers; B Biesma; A-M C Dingemans; A D Vincent; O Dalesio; H J M Groen; E F Smit Journal: Ann Oncol Date: 2013-08-28 Impact factor: 32.976
Authors: Yibo Dong; Yang Zheng; Chundi Wang; Xu Ding; Yifei Du; Laikui Liu; Wei Zhang; Wei Zhang; Yi Zhong; Yunong Wu; Xiaomeng Song Journal: Cancer Cell Int Date: 2018-08-28 Impact factor: 5.722